{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"109.89","value":"-17.3"},{"groupId":"OG001","spread":"156.60","value":"-20.90"},{"groupId":"OG002","spread":"137.33","value":"-19.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.43","value":"-22.2"},{"groupId":"OG001","spread":"105.44","value":"-26.2"},{"groupId":"OG002","spread":"88.70","value":"-24.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"51"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"127.30","value":"23.1"},{"groupId":"OG001","spread":"134.97","value":"-1.0"},{"groupId":"OG002","spread":"130.32","value":"9.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"title":"Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"103"}],"units":"Participants"}],"description":"Descriptive summary of the effect of pasireotide on GH.","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \\< 1500 μg /day.","id":"OG000","title":"Pasireotide 600 μg"},{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day","id":"OG001","title":"Pasireotide 900 μg"},{"description":"Patients received pasireotide 600 μg or 900 μg BID","id":"OG002","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Number of patients with available data differed at visits","reportingStatus":"POSTED","timeFrame":"Baseline, week 12, 24 and 48","title":"Percent Change From Baseline in Growth Hormone (GH) Values","type":"SECONDARY","unitOfMeasure":"percent change of µg/L"}